Canaccord Genuity analyst Whitney Ijem has maintained their bullish stance on VERV stock, giving a Buy rating today.
Whitney Ijem has given his Buy rating due to a combination of factors, primarily focusing on the promising progress of Verve Therapeutics’ key programs. The company’s lead program, VERVE-102, has shown significant advancement, successfully dosing patients across all three dose cohorts, which is a positive indicator of its potential efficacy.
Additionally, Verve Therapeutics has a strong financial position, ending the fourth quarter of 2024 with $524.3 million in cash, which is expected to sustain operations into mid-2027. The company’s strategic decisions, such as the anticipated earlier approval of VERVE-201 in 2028, further support the Buy rating, reflecting confidence in the company’s future growth and development trajectory.
Ijem covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Vertex Pharmaceuticals, and Arcturus Therapeutics. According to TipRanks, Ijem has an average return of -2.5% and a 37.43% success rate on recommended stocks.
In another report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $15.00 price target.